Gastropub in Caversham wins bid to improve brunch experience
The operators of a pub near the river in Caversham have won permission to serve alcohol earlier to improve their offer for brunch.
The Griffin pub is situated in Church Road, Caversham, just a short walk away from the River Thames.
Last month, the Chef & Brewer company that runs the pub applied to sell alcohol from 8.30am each day.
The application has since been granted, with a representative from the company saying it will allow pub staff to enhance guest experience for brunch.
Persian restaurant in Caversham in trouble over riverside seating area
The Griffin has an extensive menu for both breakfast and lunch.
Now guests will be able to enjoy alcohol with their breakfast and brunch if they wish.
A spokesperson for the Griffin explained: 'We requested a variation of hours to enable us to trade earlier, with no change to closing times which will remain as they are currently.
'The earlier trading hours will enable us to enhance our guest experience for those who would like to join us for brunch.'
Experience the pulse of Reading at your fingertips! 🚨 With our flash sale, Reading Chronicle keeps you updated for less: only £3 for 3 months or save 40% on an annual subscription. Don't miss out on what's happening locally! 👇#DigitalDeal #LocalJournalism pic.twitter.com/ro6XUMoPl9
— Reading Chronicle (@rdgchronicle) April 15, 2025
The earlier operating hours were approved by Reading Borough Council's licensing department.
A statutory consultation into the application received one objection by a neighbour concerned about the possibility of the Griffin staying open later at night.
However, the objection was dismissed as not relevant, as the application was only to allow the pub to open earlier in the morning.
The Griffin now has permission to sell alcohol from 8.30am to 11.30pm Sunday to Thursday, and from 8.30am to 12.30am on Fridays and Saturdays.
The Chef & Brewer brand is owned by Greene King.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Fox News
12 hours ago
- Fox News
Celebrity chef planning pop-up bakery at historic 16th century home, documents show
Celebrity chef Jamie Oliver is apparently seeking to turn a former stable block at his historic home into a pop-up takeaway bakery, news agency SWNS reported. The small pop-up would run in August only. The English chef has applied for planning permission to change the use of the former block to serve baked goods, sandwiches and coffee at his home on a month-long trial. "There isn't anything definite, just ideas at this stage," a representative told Fox News Digital. If approved, the bakery would operate on the grounds of Spains Hall in England, a Grade I-listed home built around 1570 in an area that has been used to host weddings. "The proposed temporary change of use offers the opportunity to trial a new small-scale commercial use within a rural location, which will not cause any detrimental heritage, traffic or amenity impacts," a statement from the chef's representatives to SWNS said. Grade I-listed buildings in the United Kingdom are structures of exceptional national, architectural or historical importance. They represent the highest level of protection under the planning system, according to Historic England's website. Oliver, who is listed as the applicant on plans submitted to Braintree District Council, has submitted several supporting documents via his representatives. He outlined the proposal to open the bakery throughout August, operating seven days a week from 9 a.m. to 5 p.m. It is estimated that six employees would be needed for the bakery and deliveries would be made three times a week. Said Oliver's representatives, "The existing kitchen within the building will be used for food preparation." They added, "Public access would be restricted to the main room open plan within the building plus the toilets, both of which are on the ground floor." The application stated that customers would use the existing parking in the back of the stable block, while an extra area would be available for an overflow if needed. Oliver's representatives said the proposals would have "no impact on the scale, amount, design, layout or access to the site." "No physical alterations are required to the building internally or externally in support of the proposals and there is no impact on any areas of soft landscaping or habitat." Since the Middle Ages, the house and estate in Finchingfield, Essex, have been in the ownership of just three families. It was sold to Oliver in 2019. The coach house and stable block originally date from the 18th century and were first listed in 1967, when they were used as stables. In recent years, it has been used to host weddings and other functions, SWNS reported. No public comments have been registered so far and a decision on the application will be made by the council later. For more Lifestyle articles, visit Oliver had previously sought permission for repair work to the property, including windows, doors and masonry. He has been credited with renovating it from a state of disrepair. The $6.8-million house serves as his family home, where he lives with his wife, Jools, and their five children. Jamie Oliver's Cookery School has also offered a cooking experience at Spains Hall, allowing guests to learn from his chefs and sample ingredients from his garden.
Yahoo
13 hours ago
- Yahoo
Anticipated Mediterranean restaurant Purslane opens on Milwaukee's east side
A highly anticipated restaurant in the former Ardent space on Milwaukee's east side is officially open for business. Purslane, which announced in December that it would take over the space at 1751 N. Farwell Ave., opened June 4. The restaurant is serving farm-driven fare inspired by flavors of the eastern Mediterranean, focusing on mezze (small plates), larger dishes meant for sharing and an expertly crafted beverage program. The restaurant comes from chef-owner Mary Kastman, former executive chef at Driftless Cafe in Viroqua, where she was named a semifinalist for Best Chef, Midwest in the 2022 James Beard Awards. Kastman started Purslane in 2024 as a pop-up concept in Viroqua before opening the brick-and-mortar space in Milwaukee. 'We're ready and excited to bring a different type of hospitality and a different concept of food to Milwaukee,' Kastman said. 'We're so thankful for the support, and really excited to show everybody what we've been up to.' Since moving into the restaurant space in February, Kastman's been hard at work transforming the space, developing the menu and working on the beverage program to deliver a unique and communal dining experience in Milwaukee. It includes a 25-seat restaurant, a casual lounge space for snacks and drinks, a curated food menu featuring seasonal ingredients, and an extensive bar program inspired by the eastern Mediterranean region, with small Wisconsin flourishes incorporated. Kastman, who has traveled extensively in Turkey and worked in the kitchens at celebrated Boston-based Mediterranean restaurants Oleana and Sarma, said a recent visit to Istanbul let her know Milwaukee is ready for her restaurant concept. 'This is where my heart is and my passion is, and I am so ready to bring this to another community,' Kastman said. 'Seeing a lot of my dear friends who live in Turkey be excited about this idea and give it their blessing has been pretty incredible.' Purslane is open 5 to 9 p.m. Tuesday to Thursday and 5 to 10 p.m. Friday and Saturday. The restaurant is currently accepting reservations via Toast up to 30 days in advance. Limited walk-in seating is available at its seven-seat bar on a first-come, first-served basis. For parties of eight or more, call the restaurant at (414) 212-8692 to make a reservation. The debut menu features 13 curated dishes, including snacks, small plates, larger plates and desserts made with seasonal ingredients sourced from local farmers. Snacks include a Persian spiced bar snack mix ($3), olives with preserved lemon and chios spice ($9), and deviled eggs with trout taramasalata, smoked trout roe and bar pine nuts ($13). Among the small plates are harissa chicken wings with preserved lemon aioli and green papaya slaw ($19), and Fattoush salad with fennel, cucumber, rhubarb, red onion, radish, pomegranate vinaigrette and sumac topped with crisped Juusto cheese ($17). Also on the small plates menu is the tuna naya ($23), which Kastman said is a favorite of hers and an homage to Ardent's signature beef tartare dish. Her rendition features raw tuna dressed in yuzu and strawberry charmoula marinade topped with crunchy togarashi rice and served with pita chips. There's even a Mediterranean take on the classic fish fry. At Purslane, cooked walleye is folded into a classic chickpea falafel base and fried up like fritters. They're served with lavash bread. tahini remoulade and brown butter pickle with fresh lettuce for wrapping the fritters like sandwiches ($21). Larger plates include sea scallops with katayifi, muhammara and strawberry shatta ($43), and oyster mushroom shish with white bean, asparagus, bok choi, spicy feta, kalamata olive and breadcrumbs ($33). The Ali Nazik beef kebab, made with smoky eggplant yogurt and shishito ($37), is especially close to Kastman's heart. Inspired by chef and mentor Musa Dağdeviren, author of 'The Turkish Cookbook,' the dish from the Gaziantep region of Turkey is what Kastman called 'a holy trinity of Turkish cuisine,' featuring smoky yogurt, eggplant and beef, served terrine-style with a shishito and roasted red pepper sauce. For dessert, expect olive oil cake with sour cherry and tahini mascarpone ($11), and Kaymek semifreddo made with clotted cream and served with strawberry, rhubarb and pistachio bohsalino ($9). Kastman said guests are encouraged to share with their dining partners, as the Purslane experience is enhanced by the feeling of communal dining. 'My dream is that everybody would come in and their tables would be full of all of these little plates and they're all eating and trying new things and experiencing all of these different flavors,' Kastman said. 'If somebody can walk out of here saying, 'I've never had carrots like this or I've never tasted something like that,' that's the greatest compliment — for somebody to see something in a new light.' Purslane takes its bar program as seriously as its food. Beverage Director Kyle Yost, formerly of 2025 James Beard Award finalist Agency cocktail lounge, has created a variety of handcrafted beverages ($15 each) inspired by classic cocktails, including a white negroni made with gin infused with toasted pine nuts, a Spanish gin and tonic garnished with fresh herbs, a Manhattan with fenugreek and caraway-infused rye whiskey, and a spin on the daisy cocktail with strawberry, lime ancho verde and arak, a Levantine spirit similar to Greek Ouzo that's made with anise seeds. Nonalcoholic beverages include spirit-free cocktails ($12 each) like a sage gimlet and spicy honey tonic with amber chili honey, as well as drinks from Milwaukee-made Rishi Tea and Sugar Leaf Coffee Roasterie. Russell Tinsley, former general manager at Ardent, worked with Kastman to create the extensive wine list, featuring varietals from Greek, Turkey, Lebanon, France and Spain. Wines are available by the glass ($13 to $16) and the bottle. The restaurant also will serve a selection of Spanish, Turkish and locally made beer. Kastman said she wanted Purslane to capture the comfort and community culture she's come to love in her many visits to the eastern Mediterranean region. On a recent visit, she met up with Dağdeviren, who took her group shopping at the Grand Bazaar, one of the oldest and largest covered markets in the world. Along with inspiration, she brought back textiles, lighting fixtures, ceramics and plates to use and display at the restaurant. 'I wanted to keep the cozy nature the space already had, but give it a bit more of a Mediterranean feel,' she said. The main dining area kept the terracotta-colored ceiling from the space's Ardent days, but now also has vibrant, Mediterranean-inspired teal paint on the walls. A large floral mural on a wall at the back of the main dining room was created by Viroqua artist Audra Grosz of Tattoo Zuzu, a tattoo shop. The left-side space at Purslane, which was most recently home to Ardent's tasting room, acts as an informal lounge for those who want a snack and a drink — either while waiting for a table or as a casual pop-in, no matter if you're dining next door. Dubbed the Meyhane lounge, the space has seating for 20, including at tables, the bar and a small couch. The area is open for walk-ins during Purslane's regular business hours Thursday to Saturday. Anyone is welcome to order snacks, sip a glass of wine and maybe play a game of backgammon on one of the provided sets. In the lounge, Viroqua-based artists Gabriela Jiménez Marván and Ryan Rothweiler of Marván Art & Design designed and painted a wall mural featuring the restaurant's namesake plant, the purslane. In the same area, Purslane has a retail space, selling items like Milwaukee's Sugar Leaf coffee, spice blends, hats and, in the coming weeks, grab-and-go food options like hummus and mezze offerings. The Meyhane lounge also can be reserved for private parties and events. Kastman, her husband, Erik, and their two children have been settling into their Shorewood home since moving from Viroqua in December. 'With our two little ones at home, he's really been the number-one super dad, and has been incredibly supportive, helping me fix things up and make all of the aesthetic changes,' Kastman said, adding that he also serves as Purslane's official 'tech guy.' Kastman is grateful for local friends like Amilinda chef-owner Gregory León, who's been supportive from the start, offering feedback and opening his restaurant for Purslane pop-ups. Her friend and mentor of 20 years, Justin Carlisle, former chef-owner of Ardent, has played an integral role in making Purslane a reality. Aside from traveling with her to Istanbul, Kastman said Carlisle was always there to help with his institutional knowledge about the kitchen, the restaurant space and the community. 'The whole evolution of how this came to be is really meaningful to me,' Kastman said. 'Coming in to this space and ushering it into a new chapter of interesting culinary things happening on Farwell Avenue, it's so special. If I can help change the conversation or just make people have a conversation — that's what it's all about.' This article originally appeared on Milwaukee Journal Sentinel: New Milwaukee restaurant Purslane now open in old Ardent space
Forbes
2 days ago
- Forbes
This Cancer Survivor, Now Biotech CEO, Is In A Race To Help Others Live Longer
Maky Zanganeh was born in Tehran in 1970, nine years before the Islamic Revolution convulsed Iran. She remembers one night in particular, when the military police tear-gassed a house at the end of the cul-de-sac next to where her family lived and sprayed it with machine gun fire. She and her two older sisters were home alone. 'In the morning, we woke up at 7 o'clock and had to go to school as if nothing happened,' she says matter-of-factly. 'That was my life when I was in Iran.' Mauricio Candela for Forbes That preternatural composure and no-nonsense attitude has helped Zanganeh navigate a life filled with more twists and turns than a Persian bazaar. A couple years after that horrific night in Tehran, Zanganeh's parents, both architects, fled Iran for Germany. She got a degree in dentistry, then an MBA, but ended up working for an American medical robotics outfit, where she met Bob Duggan, a prominent Scientologist, serial entrepreneur and eventual billionaire with whom she would have a son and later marry. She earned hundreds of millions as an investor and executive, speaks four languages (Farsi, German, English, French), survived breast cancer and runs, as co-CEO with Duggan, Miami-based Summit Therapeutics, a Nasdaq-listed biotech that has minted her a $1.5 billion fortune of her own. That wealth has landed Zanganeh, now 54, on Forbes' list of America's Richest Self-Made Women (at No. 23) for the first time. She is one of 38 self-made female U.S. billionaires on the list, and one of just five to have made a billion-dollar-plus fortune in health care. When she and Duggan took over Summit in 2020, the company had less than $1 million in revenue, tens of millions in losses and just one promising drug in its pipeline, an antibiotic that was shelved in 2022. In less than five years, Zanganeh and Duggan—who married in December—have become biotech stars. Key to their success: licensing an overlooked cancer drug candidate from a company in China. That drug, ivonescimab, now seems likely to be a blockbuster. In a clinical trial last year, it outperformed Keytruda, the world's best-selling drug, which generated nearly $30 billion in 2024 sales for Merck. Investors have driven up Summit shares 575% over the past 12 months, giving it a recent market capitalization of nearly $21 billion, despite having no revenue. 'I think of her as probably the most underrated executive in all of biotech,' says Ken Clark, a partner at law firm Wilson Sonsini Goodrich & Rosati, who for more than three decades has worked with hundreds of biotech companies and served on multiple boards—including that of Summit Therapeutics. According to Clark, Zanganeh stands out because of how she and Duggan, neither of whom comes from a traditional biotech background, work together to question established wisdom and get things done quickly in unconventional ways. Ivonescimab is now in multiple Phase III trials for different forms of lung cancer, and Summit plans to submit an application for FDA approval by the end of the year. It can't come too soon. Even after advances in treatment and detection of lung cancer over the past two decades, 125,000 Americans die from the disease each year—more than twice the number of deaths from any other cancer, per the National Cancer Institute. What's novel about Summit's drug is how it goes after the cancer in two ways. It stimulates the immune system to attack the cancer cells while also starving the cancer by cutting off blood supply to the tumors. Based on the clinical trial in China last year, the two-pronged approach works. Those on Summit's drug went a median 11.1 months before the cancer returned, compared to 5.8 months for those taking Keytruda. The results, announced last September, led Summit's stock to more than double in four days. Zanganeh's journey from schoolgirl in Tehran to Miami biotech CEO took an unusual route. In 1984, five years after the Shah of Iran was overthrown, her parents moved with her to Germany. Zanganeh settled down with an uncle in Oldenburg, a small city about 30 miles from Bremen, while her parents continued to shuttle between Europe and Iran. Old-fashioned values prevailed: good manners, good health and lots of studying. 'Education was a top priority,' Zanganeh says. Her older sisters both went to medical school in Strasbourg, France. She chose to study dentistry instead and graduated from Louis Pasteur University (now the University of Strasbourg) in 1995. She soon realized dentistry was not for her. 'It was like being in a box every day, doing the same thing,' she says. In 1997, a friend of her sister's told Zanganeh about her job at a U.S. company called Computer Motion, which manufactured robotic arms used to perform minimally invasive surgery. Zanganeh was fascinated and landed a job in the Strasbourg office. Her father convinced her that if she was going to go into business, she would need an MBA, so studying part-time she earned one from Schiller International University in 1998. At 28, Zanganeh was promoted to oversee Computer Motion's business in Europe and the Middle East, which involved visiting surgeons in Dubai, Saudi Arabia and Egypt, introducing them to what was then a new technology. That's also when Zanganeh began working with Computer Motion's CEO, Bob Duggan, who had invested in the company back in 1989. Duggan, now 81, was the yin to Zanganeh's yang. She had been a diligent student and dedicated employee who earned an advanced degree. He had spent at least five years at UC Santa Barbara and UCLA without earning a degree, was a passionate surfer and had worked for himself, except for a brief three-year stint, since he started mowing lawns as a teenager. He's an idea guy with an analytical mind who thinks and talks fast, while Zanganeh excels at process and execution. 'We're very simpatico,' Duggan says. 'She knows all the details and she's got a photographic memory. I'm a visionary. I can see around corners.' In 2003, after Duggan sold Computer Motion to Intuitive Surgical, they began looking for the next big thing. Zaganeh, who was then working for Duggan's personal investment firm, became intrigued with cancer drug developer Pharmacyclics, a money-losing public company with a potentially promising drug—she says she picked it from a list of 15 companies that came in via fax from an analyst. One of Duggan's sons had died of brain cancer, so the company's purpose resonated. Both Duggan and Zanganeh invested in Pharmacyclics in April 2004; Zanganeh sold her Intuitive Surgical shares and borrowed from the bank to come up with the cash. By 2008 Duggan had increased his stake to the point where he controlled the Sunnyvale, California–based company and installed himself as CEO. Zanganeh also joined, first as vice president of business development and later as chief operating officer. In 2011, armed with a fresh early-stage cancer drug (the first one failed), Duggan began talking up a partnership with Johnson & Johnson, which needed to boost its cancer drug pipeline. Zanganeh made it come to fruition. 'She's a force of nature. She is so thoughtful, so prepared, so data-driven, and then she takes that and makes things happen,' says Michael Gaito, global chairman of investment banking and health care at JPMorgan, whose firm advised Pharmacyclics in when it was sold to AbbieVie in 2015. Zanganeh negotiated a worldwide partnership with J&J that allowed the smaller Pharmacyclics to book the U.S. revenue from the new cancer drug, rather than the typical arrangement in which it would go to the big pharma partner. She also negotiated upfront payments over two years of $400 million. 'The terms of it were revolutionary at the time,' Gaito says. Adds Summit board member Clark: 'She really drove it.' Pharmacyclics' drug, Imbruvica, ended up being a blockbuster treatment for chronic lymphocytic leukemia, one of the most common forms of leukemia in adults. It is far less toxic than the chemotherapy that was the previous standard treatment. A surge in Pharmacyclics' stock price first landed Duggan on Forbes' Billionaires list in 2013, the year Imbruvica got FDA approval. Two years later, drug giant AbbVie bought the company for $21 billion. Zanganeh, who had invested about $1 million in the company, walked away with $225 million before taxes. The cash was especially welcome since it enabled Zanganeh, who had been raising her son, Shaun, on her own, to spend more time being a mom. Back in 2006, when he was born, Zanganeh was traveling so much for work, researching investments with Duggan, that her mother, who lived in France, raised Shaun until he was 5, with Zanganeh flying to France every two weeks to visit. (Duggan recently acknowledged that Shaun is his son.) In 2019, Zanganeh was on a trip to France to visit her father, who was having surgery to remove a cancerous tumor, when she found a lump that turned out to be Stage 2 breast cancer. She had surgery at the same hospital as her dad, then flew home to the U.S., where she started chemotherapy two weeks before Covid-19 lockdowns began in March 2020. It didn't go smoothly: Her heart and lungs practically shut down and she had to be hospitalized. She had bone pain and chronic vomiting. 'I was really, really sick,' she says. 'All of the time, you have this fear. What if it metastasizes?' She says the silver lining was that she got to experience the same challenges as many of the patients her industry exists to serve. During this time, Duggan targeted another struggling biotech. He spent $63 million buying 60% of Summit Therapeutics' shares and became CEO in April 2020. Seven months later, chemo treatments behind her, Zanganeh joined as chief operating officer and board member. In July 2022, she was appointed co-CEO. After initial plans to develop a new antibiotic sputtered, the pair hired a handful of former Pharmacyclics employees and sent them on a quest to find a new cancer drug—anywhere in the world. Fong Clow, a Pharmacyclics veteran originally from China, suggested looking in her home country. In mid-2022 the Summit team zeroed in on ivonescimab, which was made by a Hong Kong–listed firm called Akeso and already in Phase III trials. At the time, there was some hesitation in the industry about partnering with a Chinese drugmaker. In March 2022, the FDA declined to approve a lung cancer drug that Eli Lilly had licensed from China's Innovent Biologics. That's one possible reason Akeso, which had presented some promising research at ASCO, the big annual oncology conference that year, didn't attract big pharma. It wasn't a problem for Zanganeh and Duggan. 'They're just not bound by conventional thinking,' says board member Clark. They were, however, bound by Summit's finances. In September 2022 the company had just over $120 million of cash on hand and a market cap of about $200 million. But Michelle Xia, the founder and CEO of Akeso—who had worked for Bayer and other pharmaceutical companies in the U.S. after getting a Ph.D. in molecular biology in the U.K.—bonded with Zanganeh and Duggan. The two teams quickly discovered they had similar entrepreneurial cultures. 'They found me, and I think it's a perfect fit,' Xia says. In December 2022 the two companies agreed to license Akeso's drug for $500 million upfront (Summit had to borrow from Duggan and Zanganeh to cover the sum) and $4.5 billion in potential milestone payments if ivonescimab gets approved. Zanganeh is optimistic on that front. Ivonescimab is undergoing 11 Phase III trials around the world. Results so far have been mostly positive, though on May 30 the company reported that it missed one of two primary targets–for overall survival–in one of the trials, sending Summit shares plummeting 30% that day. In a June 1 note, Cantor Fitzgerald biotech analyst Eric Schmidt wrote, 'We think the markets got it wrong,' explaining that the trial showed very positive results for the other target, time without disease progression–and that this particular trial is for a small subset of lung cancer patients. As a cancer survivor, Zanganeh knows there is no time to waste. 'The speed of [our] decision making is fast,' she says. 'You want to make sure that you can really help all these patients.' Disclosure: Maky Zanganeh, Summit Therapeutics' co-CEO, published a book in February with Forbes Books, a licensed partner of Forbes.
